Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Investigation of Individualised Antisense Oligonucleotides (ASOs) in People With Unique Genetic Variants Causing Severely Debilitating, Life Threatening (SDLT) Central Nervous System (CNS) Conditions.

Next Previous
Trial Profile

Investigation of Individualised Antisense Oligonucleotides (ASOs) in People With Unique Genetic Variants Causing Severely Debilitating, Life Threatening (SDLT) Central Nervous System (CNS) Conditions.

Status: Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Mar 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Antisense oligonucleotide EveryONE Medicines (Primary)
  • Indications CNS disorders
  • Focus Adverse reactions
  • Acronyms EOM-MP1
  • Sponsors EveryONE Medicines

Most Recent Events

  • 17 Mar 2026 Planned number of patients changed to 1.
  • 17 Mar 2026 Planned End Date changed from 30 Jun 2028 to 31 Oct 2026.
  • 17 Mar 2026 Planned primary completion date changed from 31 May 2028 to 30 Sep 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top